Overview Dividends

(WST) West Pharmaceutical - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9553061055

Stoppers, Seals, Syringes, Cartridges, Self-Injection Devices

EPS (Earnings per Share)

EPS (Earnings per Share) of WST over the last years for every Quarter: "2020-09": 1.15, "2020-12": 1.34, "2021-03": 2.05, "2021-06": 2.46, "2021-09": 2.06, "2021-12": 2.04, "2022-03": 2.3, "2022-06": 2.47, "2022-09": 2.03, "2022-12": 1.77, "2023-03": 1.98, "2023-06": 2.11, "2023-09": 2.16, "2023-12": 1.83, "2024-03": 1.56, "2024-06": 1.52, "2024-09": 1.85, "2024-12": 1.82, "2025-03": 1.45, "2025-06": 1.84, "2025-09": 1.96,
EPS Growth (3y CAGR): 3.78%
EPS Trend (3y Corr): -30.4%
Last SUE: 1.45σ
Qual. Beats: 3

Revenue

Revenue of WST over the last years for every Quarter: 2020-09: 548.3, 2020-12: 580.3, 2021-03: 671, 2021-06: 724.1, 2021-09: 706.6, 2021-12: 729, 2022-03: 719.7, 2022-06: 771.6, 2022-09: 686.4, 2022-12: 708.4, 2023-03: 715.9, 2023-06: 754.2, 2023-09: 747.5, 2023-12: 732.1, 2024-03: 695.3, 2024-06: 702, 2024-09: 746.9, 2024-12: 748.5, 2025-03: 698.2, 2025-06: 766.2, 2025-09: 804.3,
Revenue Growth (3y CAGR): 4.73%
Revenue Trend (3y Corr): 44.3%
Last SUE: 0.72σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 42.8%
Value at Risk 5%th 48.3%
Relative Tail Risk -31.51%
Reward TTM
Sharpe Ratio -0.05
Alpha -24.33
Character TTM
Hurst Exponent 0.650
Beta 0.533
Beta Downside 0.565
Drawdowns 3y
Max DD 53.79%
Mean DD 20.05%
Median DD 18.11%

Description: WST West Pharmaceutical October 16, 2025

West Pharmaceutical Services (WST) designs, manufactures, and sells containment and delivery systems for injectable drugs across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. The company operates two segments: Proprietary Products, which provides stoppers, seals, syringe and cartridge components, advanced reconstitution and mixing technologies, and integrated services such as analytical labs and regulatory support; and Contract-Manufactured Products, which delivers automated assembly of devices for surgical, diagnostic, ophthalmic, injectable, and consumer-health applications.

Key recent metrics show FY 2023 revenue of approximately $2.5 billion, an operating margin near 13 %, and earnings per share of $5.30, with a modest dividend yield of about 1.2 %. Growth is being driven by the expanding biologics market-projected to outpace small-molecule drugs at a CAGR of ~8 % through 2028-and heightened demand for sterile, high-integrity packaging amid tighter regulatory scrutiny on drug safety.

If you want a deeper, data-rich view of West’s valuation and competitive positioning, a quick look at ValueRay’s analyst toolkit can help you surface the most material assumptions and scenario analyses.

WST Stock Overview

Market Cap in USD 18,715m
Sub-Industry Health Care Supplies
IPO / Inception 1978-01-13
Return 12m vs S&P 500 -25.8%
Analyst Rating 4.69 of 5

WST Dividends

Metric Value
Dividend Yield 0.33%
Yield on Cost 5y 0.31%
Yield CAGR 5y 5.66%
Payout Consistency 96.5%
Payout Ratio 12.0%

WST Growth Ratios

Metric Value
CAGR 3y 4.49%
CAGR/Max DD Calmar Ratio 0.08
CAGR/Mean DD Pain Ratio 0.22
Current Volume 1308.6k
Average Volume 693.1k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (491.7m TTM) > 0 and > 6% of Revenue (6% = 181.0m TTM)
FCFTA 0.09 (>2.0%) and ΔFCFTA 0.48pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 39.37% (prev 35.95%; Δ 3.42pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.17 (>3.0%) and CFO 693.8m > Net Income 491.7m (YES >=105%, WARN >=100%)
Net Debt (-325.5m) to EBITDA (772.1m) ratio: -0.42 <= 3.0 (WARN <= 3.5)
Current Ratio 2.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (72.7m) change vs 12m ago -0.95% (target <= -2.0% for YES)
Gross Margin 35.59% (prev 35.00%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 77.55% (prev 78.26%; Δ -0.71pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 433.6 (EBITDA TTM 772.1m / Interest Expense TTM 1.40m) >= 6 (WARN >= 3)

Altman Z'' 10.49

(A) 0.29 = (Total Current Assets 1.82b - Total Current Liabilities 635.4m) / Total Assets 4.11b
(B) 1.04 = Retained Earnings (Balance) 4.26b / Total Assets 4.11b
warn (B) unusual magnitude: 1.04 — check mapping/units
(C) 0.16 = EBIT TTM 607.0m / Avg Total Assets 3.89b
(D) 3.96 = Book Value of Equity 4.18b / Total Liabilities 1.05b
Total Rating: 10.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.18

1. Piotroski 6.50pt
2. FCF Yield 2.06%
3. FCF Margin 12.56%
4. Debt/Equity 0.10
5. Debt/Ebitda -0.42
6. ROIC - WACC (= 8.22)%
7. RoE 17.33%
8. Rev. Trend 44.26%
9. EPS Trend -30.36%

What is the price of WST shares?

As of November 21, 2025, the stock is trading at USD 257.77 with a total of 1,308,586 shares traded.
Over the past week, the price has changed by -3.33%, over one month by -6.16%, over three months by +4.71% and over the past year by -17.02%.

Is WST a buy, sell or hold?

West Pharmaceutical has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy WST.
  • Strong Buy: 10
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the WST price?

Issuer Target Up/Down from current
Wallstreet Target Price 350.8 36.1%
Analysts Target Price 350.8 36.1%
ValueRay Target Price 265.6 3%

WST Fundamental Data Overview November 20, 2025

Market Cap USD = 18.72b (18.72b USD * 1.0 USD.USD)
P/E Trailing = 38.5964
P/E Forward = 34.965
P/S = 6.2015
P/B = 6.1867
P/EG = 3.3151
Beta = 1.165
Revenue TTM = 3.02b USD
EBIT TTM = 607.0m USD
EBITDA TTM = 772.1m USD
Long Term Debt = 202.7m USD (from longTermDebt, last quarter)
Short Term Debt = 22.9m USD (from shortTermDebt, last quarter)
Debt = 303.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -325.5m USD (from netDebt column, last quarter)
Enterprise Value = 18.39b USD (18.72b + Debt 303.0m - CCE 628.5m)
Interest Coverage Ratio = 433.6 (Ebit TTM 607.0m / Interest Expense TTM 1.40m)
FCF Yield = 2.06% (FCF TTM 379.1m / Enterprise Value 18.39b)
FCF Margin = 12.56% (FCF TTM 379.1m / Revenue TTM 3.02b)
Net Margin = 16.30% (Net Income TTM 491.7m / Revenue TTM 3.02b)
Gross Margin = 35.59% ((Revenue TTM 3.02b - Cost of Revenue TTM 1.94b) / Revenue TTM)
Gross Margin QoQ = 36.49% (prev 35.66%)
Tobins Q-Ratio = 4.48 (Enterprise Value 18.39b / Total Assets 4.11b)
Interest Expense / Debt = 0.03% (Interest Expense 100.0k / Debt 303.0m)
Taxrate = 19.54% (34.0m / 174.0m)
NOPAT = 488.4m (EBIT 607.0m * (1 - 19.54%))
Current Ratio = 2.87 (Total Current Assets 1.82b / Total Current Liabilities 635.4m)
Debt / Equity = 0.10 (Debt 303.0m / totalStockholderEquity, last quarter 3.05b)
Debt / EBITDA = -0.42 (Net Debt -325.5m / EBITDA 772.1m)
Debt / FCF = -0.86 (Net Debt -325.5m / FCF TTM 379.1m)
Total Stockholder Equity = 2.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.98% (Net Income 491.7m / Total Assets 4.11b)
RoE = 17.33% (Net Income TTM 491.7m / Total Stockholder Equity 2.84b)
RoCE = 19.97% (EBIT 607.0m / Capital Employed (Equity 2.84b + L.T.Debt 202.7m))
RoIC = 16.07% (NOPAT 488.4m / Invested Capital 3.04b)
WACC = 7.85% (E(18.72b)/V(19.02b) * Re(7.98%) + D(303.0m)/V(19.02b) * Rd(0.03%) * (1-Tc(0.20)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.55%
[DCF Debug] Terminal Value 77.77% ; FCFE base≈356.1m ; Y1≈343.9m ; Y5≈340.2m
Fair Price DCF = 84.22 (DCF Value 6.06b / Shares Outstanding 71.9m; 5y FCF grow -4.67% → 3.0% )
EPS Correlation: -30.36 | EPS CAGR: 3.78% | SUE: 1.45 | # QB: 3
Revenue Correlation: 44.26 | Revenue CAGR: 4.73% | SUE: 0.72 | # QB: 0

Additional Sources for WST Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle